开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

已收盘 12-15 15:48:31

1.930

-0.050

-2.53%

最高2.000	最低1.910	成交量28.20万
今开2.000	昨收1.980	日振幅4.55%
总市值9.63亿	流通市值9.63亿	总股本4.99亿
成交额54.80万	换手率0.06%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.93,"timestamp":1765784911022,"preClose":1.98,"halted":0,"volume":282000,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.39847585895051396,"marketStatus":"已收盘","change":-0.05,"latestTime":"12-15 15:48:31","open":2,"high":2,"low":1.91,"amount":547950,"amplitude":0.045455,"askPrice":1.94,"askSize":44500,"bidPrice":1.93,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.42688355359102265,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.98,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.318356,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939/tweets","defaultTab":"tweets","newsList":[{"id":"2591648625","title":"争议药物\"九期一\"获新生？复星医药14亿元收购绿谷医药重启临床与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648625","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648625?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:51","pubTimestamp":1765795877,"startTime":"0","endTime":"0","summary":"此次收购案后，复星医药方面表示，甘露特钠胶囊重新开展商业化生产和销售前，还需补充完成目前尚在开展的上市后确证性临床试验并获得国家药品审评部门批准。本次收购完成后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期尽快实现获批；并适时开展相关适应症的国际多中心临床试验，惠及更多阿尔茨海默病患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765795546434638047","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK0175","BK0188","BK1191","BK1515","BK0028","BK0187","BK0196","BK0060","BK1593","BK0012","600196","09939","BK1161","02196","BK0096","BK1574","BK0239","159938"],"gpt_icon":0},{"id":"2591612068","title":"复星医药：控股子公司拟出资14.12亿元投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612068","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612068?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791813,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月15日，复星医药(600196.SH)公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591807093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591807093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1191","BK0012","BK0096","BK1574","BK1515","09939","BK0060","BK0188","BK0175","BK0239","BK0196","600196","BK0183","BK0187","BK0028","02196","159938","BK1161"],"gpt_icon":0},{"id":"2591611929","title":"香港医疗设备采购商柏威医药(AED.US)申请美股IPO，拟筹资700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591611929","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591611929?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:55","pubTimestamp":1765788951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，总部位于香港的医疗设备和软件采购商柏威医药于上周四向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多700万美元资金。该公司计划以每股7至9美元的价格发行90万股股票，筹资700万美元。按拟议发行区间的中值计算，柏威医药的市值将达到8700万美元。这家总部位于香港的公司成立于2003年，在截至2025年3月31日的12个月内录得营业收入2500万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","BK1574","09939","159873","BK1161"],"gpt_icon":0},{"id":"2591861598","title":"12月15日三生国健跌5.83%，交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591861598","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591861598?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:35","pubTimestamp":1765784122,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日三生国健跌5.83%，收盘报60.7元，换手率0.85%，成交量5.24万手，成交额3.22亿元。重仓三生国健的前十大公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为70.27。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","688336","BK1574","BK1161","BK0239","BK1515","159938"],"gpt_icon":0},{"id":"2591691376","title":"恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591691376?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:11","pubTimestamp":1765768311,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数跌幅扩大至2.75%，医药股普遍走低，科伦博泰生物(06990)跌7.07%，百济神州(06160)跌5.35%，复宏汉霖(02696)跌5.32%，荣昌生物(09995)跌4.05%，康方生物(09926)跌3.61%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU1961090484.USD","LU2488822045.USD","BK1161","LU2778985437.USD","LU1303224171.USD","LU2476274308.USD","LU0588546209.SGD","LU2476274720.SGD","LU0417516571.SGD","LU2399975544.HKD","LU0348767384.USD","LU1794554557.SGD","06160","LU0561508036.HKD","159506","LU0417516738.SGD","LU0348825331.USD","BK1500","BK1583","LU0634319403.HKD","LU2328871848.SGD","IE00BPRC5H50.USD","LU0348735423.USD","LU1720050803.USD","LU1770034418.SGD","IE00B5MMRT66.SGD","09926","LU1251922891.USD","IE00B543WZ88.USD","159938","09939","BK1574","LU0307460666.USD","06990","02696","BK1515","LU0348783233.USD","LU1719994722.HKD","HK0000165453.HKD","09995","LU0348766576.USD","LU0417516902.SGD","BK1588","LU0540923850.HKD","LU0348784397.USD","LU1969619763.USD","LU0196878994.USD"],"gpt_icon":0},{"id":"2591956296","title":"港股开盘 | 恒指低开1% 医药板块跌幅居前 歌礼制药(01672)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591956296","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591956296?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:30","pubTimestamp":1765762255,"startTime":"0","endTime":"0","summary":"恒生指数低开1%，恒生科技指数跌1.34%。盘面上，辅助生殖概念活跃，三胎概念股锦欣生殖开涨约3%；医药板块跌幅居前，歌礼制药跌超5%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","HHImain","HSI","MHImain","159938","513600","01477","BK4614","02833","BK1515","MCHmain","09939","YANG","01672","BK1191","HSImain"],"gpt_icon":0},{"id":"2591466597","title":"A股医药股，利好来了！今晚，密集公告！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591466597","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591466597?lang=zh_cn&edition=full","pubTime":"2025-12-14 20:39","pubTimestamp":1765715940,"startTime":"0","endTime":"0","summary":"多只医药股发布利好消息。　　今晚，九安医疗公告，美国子公司四联检、三联检产品获得美国FDA上市前通知，涉及的产品包括甲型流感、乙型流感、COVID-19及RSV呼吸道合胞病毒四联检测家用试剂盒等。　　开源证券表示，当前纳入医保+商保的创新药大多处于未放量以及低基数阶段，随着医保支持创新药的政策红利持续释放，纳入双目录的创新药收入有望快速提升，患者有望持续受益，同时相关创新药企也随之迎来弹性增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-14/doc-inhauqsx4667847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1574","BK1161","159982","399300","BK1515","159938"],"gpt_icon":0},{"id":"2591650105","title":"佐力药业最新公告：拟3.56亿元收购未来医药多种微量元素注射液资产组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650105","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650105?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:39","pubTimestamp":1765701597,"startTime":"0","endTime":"0","summary":"佐力药业公告称，公司于12月12日与西藏未来生物医药股份有限公司及其两家全资子公司许昌未来制药有限责任公司和合肥市未来药物开发有限公司签署了《多种微量元素注射液资产组收购协议书》，拟以总价（含税）3.56亿元收购其多种微量元素注射液资产组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400003927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK1515","BK0042","BK1161","09939","BK1574","300181","159938"],"gpt_icon":0},{"id":"2591636704","title":"同源康医药-B公布董事会成员名单及委员会任职情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2591636704","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591636704?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:28","pubTimestamp":1765535306,"startTime":"0","endTime":"0","summary":"金吾财讯 | 同源康医药-B于2025年12月12日公布董事会成员名单及其在董事会各委员会的任职情况。公告显示，公司董事会由1名执行董事、5名非执行董事及4名独立非执行董事组成。吴玉生博士担任科学委员会主席及提名委员会成员，冷雨婷博士担任薪酬及考核委员会主席及审计委员会成员，蒋晓林先生担任提名委员会主席及薪酬及考核委员会成员。其他董事亦在各委员会中担任相应职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512121852569539c62a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512121852569539c62a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02410","09939","BK1574","BK1161"],"gpt_icon":0},{"id":"2590557903","title":"同源康医药-B(02410)：江晓林获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557903","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590557903?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:32","pubTimestamp":1765528338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，江晓林先生(江先生)已获委任为独立非执行董事、董事会审计委员会(审计委员会)主席、董事会薪酬与考核委员会(薪酬委员会)成员及提名委员会(提名委员会)成员，自2025年12月12日起生效。江先生自2025年12月12日起获委任后，随即获委任为审计委员会主席以及薪酬委员会成员及提名委员会成员。本公司亦宣布，自2025年12月12日起，非执行董事顾虹博士获委任为审计委员会成员，非执行董事李钧博士不再担任审计委员会成员。为将更多时间投入其他业务和个人事务，李钧博士不再担任审计委员会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1161","09939","BK1515","02410"],"gpt_icon":0},{"id":"2591360836","title":"每日卖空追踪 | 同源康医药-B 12月12日卖空量成交3.7万股，卖空比例为1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591360836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591360836?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528228,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间12月12日，涨2.02%，卖空量成交3.7万股，较上一交易日增加221.74%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165451a69b843a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165451a69b843a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1515","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"2591068748","title":"劲方医药-B12月12日主力净流出93.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2591068748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591068748?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:16","pubTimestamp":1765527364,"startTime":"0","endTime":"0","summary":"12月12日, 劲方医药-B股价跌0.70%，报收28.18元，成交金额2087.2万元，换手率0.22%，振幅4.86%，量比2.28。劲方医药-B今日主力资金净流出93.1万元，上一交易日主力净流入137.3万元。该股近5个交易日上涨1.29%，主力资金累计净流入187.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入293.0万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162917a4445eda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162917a4445eda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","09939","BK1574","BK1161","02595"],"gpt_icon":0},{"id":"2590527184","title":"广药老矣，尚能战否？老牌医药巨头的创新转型与增长焦虑","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527184","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590527184?lang=zh_cn&edition=full","pubTime":"2025-12-12 13:24","pubTimestamp":1765517078,"startTime":"0","endTime":"0","summary":"文丨牛刀财经 前哨医药老牌巨头广药集团，正急于寻找新增长曲线。此前，公司还宣布进军核医疗产业，是广药集团近期最引人关注的战略动作。公开报道显示，资本运作也是该公司近期的一大动作，主要是9月底广药二期基金宣布收购南京医药11.04%的股份，成为其第二大股东。另外广药集团将通过“股权受让+协议转让”组合方式，以合计9.08亿元对价获得公司26.63%股权，正式成为其间接控股股东。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765443745974668305","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","09939","BK1574","BK1515","159938"],"gpt_icon":0},{"id":"2590292725","title":"港股异动 | 同源康医药-B(02410)早盘涨超5% 公司正在准备TY-9591附条件上市NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2590292725","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590292725?lang=zh_cn&edition=full","pubTime":"2025-12-12 11:00","pubTimestamp":1765508424,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B早盘涨超5%，截至发稿， 涨3.73%，报13.35港元，成交额2154.6万港元。据悉，艾多替尼片是同源康医药针对EGFR经典突变开发的高选择性小分子抑制剂，公司已于2024年11月完成附条件批准上市资格的224例患者入组，并已于2025年4月提交预上市申请，预计2025年4季度正式提交附条件上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","02410","09939","TY","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2590751125","title":"539%疗效突破背后：全球AGA治疗将迎新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590751125","media":"泡财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590751125?lang=zh_cn&edition=full","pubTime":"2025-12-12 10:13","pubTimestamp":1765505615,"startTime":"0","endTime":"0","summary":"大量患者因疗效不佳、安全性顾虑或用药便捷性问题放弃治疗，市场存在巨大的空白地带。Clascoterone 5%的Ⅲ期数据，不仅验证了外用ARi的治疗潜力，更打破了行业对“AGA治疗疗效有限”的固有认知。同时随着开拓药业的KX-826在2026年一季度揭盲，全球雄激素性脱发治疗市场将迎来重构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212103025a69ac5e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212103025a69ac5e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2590512559","title":"华昊中天医药-B(02563)：法院批准公司委任接管人接管子基金的申请 公司已联系接管人以推进接管程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2590512559","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590512559?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:52","pubTimestamp":1765464737,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)发布公告，内容有关赎回LFM Stable Income Fund SP的认购，开曼群岛大法院(金融服务法庭)于2025年12月3日作出判决，批准公司有关委任一名接管人接管子基金的申请。法院根据认购函的条款认定US-Biostar为债权人。公司法律顾问已与获委任接管人进行沟通，接管人将根据开曼群岛法律启动LFM Fund的清盘呈请及接管程序。公司已于2025年12月10日联系接管人以推进接管程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","09939","159938","BK1574","02563"],"gpt_icon":0},{"id":"2590354737","title":"国泰海通｜医药：政策拉动国内市场有效复苏，医疗设备招采保持快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2590354737","media":"国泰君安证券研究","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590354737?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:51","pubTimestamp":1765464660,"startTime":"0","endTime":"0","summary":"医疗设备招投标规模保持增长，25年新一轮医疗设备更新有望来临。设备更新政策持续落地，有望长周期拉动医疗设备采购水平。政策拉动国内市场有效复苏，设备类企业迎来业绩拐点。报告名称：政策拉动国内市场有效复苏，医疗设备招采保持快速增长；报告日期：2025.12.10 报告作者：江珅（分析师），登记编号：S0880525090001赵峻峰（分析师），登记编号：S0880519080017余文心（分析师），登记编号：S0880525040111重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650535240&idx=5&sn=ae2f41ad10d2da39ade9f61576e7e500&chksm=89795ab610eeb6549a6126501ce55706cfcf1daf90834080e54a3b4bf95b41b41368dba844e3&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0276","159938","BK1147","BK0184","BK1515","BK1574","BK1564","BK0183","BK0188","159873","BK0028","BK0201","BK1161","BK0012","601211","09939","02611"],"gpt_icon":0},{"id":"2590599080","title":"开启最后“倒计时”，稳健横盘成劲方医药-B(02595)“入通”关键？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590599080","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590599080?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:26","pubTimestamp":1765445193,"startTime":"0","endTime":"0","summary":"除去3只标的将以“A+H”形式获纳入外，剩下28只则有望因满足“入通门槛”获纳入，劲方医药-B便是其中之一。上市以来稳健走势成“入通”关键目前数据显示，劲方医药在本次检讨周期内的日平均市值为102.96亿港元，较最新的92.42亿港元市值门槛高出超10亿港元。从劲方医药上市以来的表现来看，经历上市前期震荡下跌后实现止跌回稳的股价走势无疑是其“冲通”的关键因素。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","BK1515","BK1161","02595","BK1574"],"gpt_icon":0},{"id":"2590596279","title":"开拓药业-B(09939):陈云飞获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2590596279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590596279?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:00","pubTimestamp":1765443634,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开拓药业-B(09939)发布公告，高维鹏先生已辞任公司非执行董事，自2025年12月11日起生效;及陈云飞先生已获委任为公司非执行董事，自2025年12月11日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2590546467","title":"劲方医药-B12月11日获主力加仓137.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590546467?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440950,"startTime":"0","endTime":"0","summary":"12月11日, 劲方医药-B股价涨2.09%，报收28.38元，成交金额1500.6万元，换手率0.16%，振幅3.67%，量比1.88。劲方医药-B今日主力资金净流入137.3万元，连续3日净流入，上一交易日主力净流入133.3万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为25.00%，平均涨幅为4.80%。该股近5个交易日下跌0.21%，主力资金累计净流入327.8万元；近20日主力资金累计净流入466.4万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162045a441f3c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162045a441f3c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","09939","02595","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0259},{"period":"3month","weight":-0.1161},{"period":"6month","weight":0.1786},{"period":"1year","weight":0.8165},{"period":"ytd","weight":1.0412}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.184167}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}